Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: An overview

Expert Review of Neurotherapeutics

Volumn 13, Issue 12, 2013, Pages 1329-1342

  Zesiewicz, Theresa A ^a,b,c   Martinez Martin, Pablo ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

dopamine agonist; non motor symptoms; Parkinson's disease; rotigotine

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE;

ANXIETY DISORDER; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; CONSTIPATION; CONTINUOUS INFUSION; DEGENERATIVE DISEASE; DEPRESSION; DIZZINESS; DOPAMINERGIC ACTIVITY; FATIGUE; HALLUCINATION; HUMAN; IMPULSE CONTROL DISORDER; LOCOMOTION; NAUSEA; NON MOTOR SYMPTOM; NONHUMAN; NORADRENERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIODIC LIMB MOVEMENT DISORDER; PREVALENCE; PSYCHOSIS; QUALITY OF LIFE; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SLEEP QUALITY; SLOW WAVE SLEEP; WAKEFULNESS;

ADMINISTRATION, CUTANEOUS; DOPAMINE; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 84887983120     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.859986     Document Type: Review

References (98)

1. Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD. J. Neurol. Sci. 289(1-2), 81-88 (2010). (NMS) of the disease
2. Chaudhuri KR, Martinez-Martin P, Schapira AH et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Mov. Disord. 21(7), 916-923 (2006
3. Barone P, Antonini A, Colosimo C et al.; PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in parkinson's disease. Mov. Disord. 24(11), 1641-1649 (2009
4. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of parkinson's disease: Diagnosis and management. Lancet Neurol. 5(3), 235-245 (2006
5. Chaudhuri KR, Schapira AH. Non-motor symptoms of parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol. 8(5), 464-474 (2009
6. Benito-León J, Cubo E, Coronell C. Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study. Mov. Disord. 27(2), 211-218 (2012
7. Lemke MR, Fuchs G, Gemende I et al. Depression and Parkinson's disease. J. Neurol. 251(Suppl. 6), VI/24-27 (2004
8. Sakakibara R, Kishi M, Ogawa E et al. Bladder, bowel, and sexual dysfunction in parkinson's disease. Parkinsons Dis. 2011, 924605 (2011
9. Richy F, Gunn A, Makaroff L, Gervasoni C. Gastrointestinal disorders in parkinson's disease: Prevalence and health outcomes in a US claims database. J. Parkinsons Dis. 1(1), 65-74 (2011
10. Martinez-Martin P, Schapira AH, Stocchi F et al. Prevalence of nonmotor symptoms in parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov. Disord. 22(11), 1623-1629 (2007
11. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of parkinson's disease. Clin. Neuropharmacol. 11(6), 512-519 (1988
12. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of parkinson's disease. Mov. Disord. 16(3), 507-510 (2001
13. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with parkinson's disease. Mov. Disord. 13(6), 895-899 (1998
14. Friedman J, Friedman H. Fatigue in parkinson's disease. Neurology 43(10), 2016-2018 (1993
15. Zesiewicz TA, Sullivan KL, Arnulf I et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74(11), 924-931 (2010
16. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in parkinson's disease: A population-based, prospective study. J. Am. Geriatr. Soc. 48(8), 938-942 (2000
17. Global Parkinson's Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in parkinson's disease: Results from an international survey. Mov. Disord. 17(1), 60-67 (2002
18. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with parkinson's disease. Mov. Disord. 26(3), 399-406 (2011
19. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with parkinson's disease? J. Neurol. Neurosurg. Psychiatry 69(3), 308-312 (2000
20. Chaudhuri KR. The dopaminergic basis of sleep dysfunction and non motor symptoms of parkinson's disease: Evidence from functional imaging. Exp. Neurol. 216(2), 247-248 (2009
21. Chaudhuri K, Surmann E, Boroojerdi B, Moran K, Ghys L, Friedman J. Association between motor and nonmotor symptoms in patients with parkinson's disease: A post hoc analysis of the Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine (RECOVER) study. Neurology 76, A175 (2011
22. Swick TJ, Surmann E, Boroojerdi B. Association between early morning motor symptoms and nocturnal sleep disturbance in patients with parkinson's disease: A post hoc analysis of the RECOVER study. Neurology 76, A175 (2011
23. Bassetti CL. Nonmotor disturbances in parkinson's disease. Neurodegener. Dis. 8(3), 95-108 (2011
24. Jenner P. The rationale for the use of dopamine agonists in parkinson's disease. Neurology 45(3Suppl. 3), S6-S12 (1995
25. Deleu D, Northway MG, Hanssens Y. An evidence-based review of dopamine receptor agonists in the treatment of parkinson's disease. Saudi Med. J. 23(10), 1165-1175 (2002
26. Steiger M, Jost W, Grandas F, Van Camp G. Risk of valvular heart disease associated with the use of dopamine agonists in parkinson's disease: A systematic review. J. Neural. Transm. 116(2), 179-191 (2009
27. Baldwin CM, Keating GM. Rotigotine transdermal patch: A review of its use in the management of parkinson's disease. CNS Drugs 21(12), 1039-1055 (2007
28. Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch for the treatment of parkinson's disease and restless legs syndrome. Drugs Today (Barc.) 46(7), 483-505 (2010
29. LeWitt PA. Levodopa for the treatment of parkinson's disease. N. Engl. J. Med. 359(23), 2468-2476 (2008
30. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: An integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin. Ther. 34(4), 966-978 (2012
31. Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord. 24(10), 1468-1474 (2009
32. Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in parkinson's disease and restless legs syndrome. Acta Neurol. Scand. 100(3), 163-167 (1999
33. Naidu Y, Logishetty K, Martin A et al. Efficacy of apomorphine infusion on mood and depression aspects of nonmotor symptoms in advanced Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl. 2), S130 (2009
34. Martinez-Martin P, Reddy P, Antonini A et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: A real life study of non motor effect. J. Parkinsons Dis. 1(2), 197-203 (2011
35. Benbir G, Guilleminault C. Pramipexole: New use for an old drug-the potential use of pramipexole in the treatment of restless legs syndrome. Neuropsychiatr. Dis. Treat. 2(4), 393-405 (2006
36. Nashatizadeh MM, Lyons KE, Pahwa R. A review of ropinirole prolonged release in parkinson's disease. Clin. Interv. Aging 4, 179-186 (2009
37. Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of parkinson's disease. Expert Opin. Pharmacother. 10(4), 677-691 (2009
38. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. The in vitro receptor profile of rotigotine: A new agent for the treatment of parkinson's disease. Naunyn. Schmiedebergs Arch. Pharmacol. 379(1), 73-86 (2009
39. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl Acad. Sci. USA 95(18), 10734-10739 (1998
40. Parsey RV, Oquendo MA, Ogden RT et al. Altered serotonin 1A binding in major depression: A [carbonyl-C-11] WAY100635 positron emission tomography study. Biol. Psychiatry 59(2), 106-113 (2006
41. Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr. Dis. Treat. 8, 123-130 (2012
42. Schmid DA, Wichniak A, Uhr M et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 31(4), 832-844 (2006
43. Trenkwalder C, Kies B, Rudzinska M et al.; Recover Study Group. Rotigotine effects on early morning motor function and sleep in parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov. Disord. 26(1), 90-99 (2011
44. Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in parkinson's disease. J. Neurol. 245(Suppl. 1), S15-S18 (1998
45. Chaudhuri KR, Martinez-Martin P, Brown RG et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov. Disord. 22(13), 1901-1911 (2007
46. Martinez-Martin P, Rodriguez-Blazquez C, Abe K et al. International study on the psychometric attributes of the non-motor symptoms scale in parkinson disease. Neurology 73(19), 1584-1591 (2009
47. Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ. Reliability and validity of the Beck depression inventory in patients with parkinson's disease. Mov. Disord. 21(5), 668-672 (2006
48. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: A review of the development, validation and application of a parkinson's disease quality of life questionnaire and its associated measures. J. Neurol. 245(Suppl. 1), S10-S14 (1998
49. Chaudhuri KR, Pal S, DiMarco A et al. The Parkinson's disease sleep scale: A new instrument for assessing sleep and nocturnal disability in parkinson's disease. J. Neurol. Neurosurg. Psychiatry 73(6), 629-635 (2002
50. Trenkwalder C, Kohnen R, Hogl B et al. Parkinson's disease sleep scale-validation of the revised version PDSS-2. Mov. Disord. 26(4), 644-652 (2011
51. Chaudhuri KR, Martinez-Martin P, Antonini A et al. Rotigotine and specific non-motor symptoms of parkinson's disease: Post hoc analysis of RECOVER. Parkinsonism Relat. Disord. 19(7), 660-665 (2013
52. Barone P, Poewe W, Albrecht S et al. Pramipexole for the treatment of depressive symptoms in patients with parkinson's disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9(6), 573-580 (2010
53. Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in parkinson's disease: A national multicenter parallel-group randomized study. J. Neurol. 253(5), 601-607 (2006
54. Rektorová I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in parkinson's disease: A national multicentre prospective randomized study. Eur. J. Neurol. 10(4), 399-406 (2003
55. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in parkinson's disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci. 17(2), 214-220 (2005
56. Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society evidence-based medicine review update: Treatments for the non-motor symptoms of parkinson's disease. Mov. Disord. 26(Suppl. 3), S42-S80 (2011
57. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 11(2), 58-65 (2000
58. Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR. Pramipexole in routine clinical practice: A prospective observational trial in parkinson's disease. CNS Drugs 17(13), 965-973 (2003
59. Pahwa R, Stacy MA, Factor SA et al.; EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology 68(14), 1108-1115 (2007
60. Czernecki V, Schüpbach M, Yaici S et al. Apathy following subthalamic stimulation in parkinson disease: A dopamine responsive symptom. Mov. Disord. 23(7), 964-969 (2008
61. Ceballos-Baumann A, Häck HJ. Rotigotine transdermal patch in combination therapy for Parkinson's disease-observations in routine clinical practice. Curr. Med. Res. Opin. 27(10), 1899-1905 (2011
62. Giladi N, Fichtner A, Poewe W, Boroojerdi B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with parkinson's disease. J. Neural. Transm. 117(12), 1395-1399 (2010
63. Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in parkinson's disease. Neurourol. Urodyn. 23(7), 689-696 (2004
64. Christmas TJ, Kempster PA, Chapple CR et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2(8626-8627), 1451-1453 (1988
65. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: Double-blind, placebo-controlled trial in parkinson disease. Arch. Neurol. 64(5), 676-682 (2007
66. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68(16), 1262-1267 (2007
67. Poewe WH, Rascol O, Quinn N et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 6(6), 513-520 (2007
68. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. Mov. Disord. 22(16), 2398-2404 (2007
69. Müller T, Erdmann C, Bremen D et al. Impact of gastric emptying on levodopa pharmacokinetics in parkinson disease patients. Clin. Neuropharmacol. 29(2), 61-67 (2006
70. Pfeiffer RF. Gastrointestinal dysfunction in parkinson's disease. Lancet Neurol. 2(2), 107-116 (2003
71. Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease: A systematic review. Parkinsonism Relat. Disord. 18(5), 433-440 (2012
72. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in parkinson's disease: Response to apomorphine. Ann. Neurol. 33(5), 490-493 (1993
73. Martinez-Castrillo JC, Vela L, Del Val J, Alonso-Canovas A. Nonmotor disorders and their correlation with dopamine: Can they be treated by currently available methods? Neurologist 17(6Suppl. 1), S9-S17 (2011
74. Trenkwalder C, Kies B, Dioszeghy P et al. Rotigotine transdermal system for the management of motor function and sleep disturbances in parkinson's disease: Results from a 1-year, open-label extension of the RECOVER study. Basal. Ganglia 2, 79-85 (2012
75. Antonini A, Bernardi L, Calandrella D, Mancini F, Plebani M. Rotigotine transdermal patch in the management of parkinson's disease (PD) and its night-time use for PD-related sleep disorders. Funct. Neurol. 25(1), 21-25 (2010
76. Scheller D, Dürmüller N, Peyron G. Continuous administration of rotigotine enhances wakefulness but may deepen sleep in 6-OHDA lesioned rats. Presented at: 2nd World Parkinson Congress. Glasgow, UK, 28 September-1 October 2010
77. Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology 61(10), 1418-1420 (2003
78. Leeman AL, O'Neill CJ, Nicholson PW et al. Parkinson's disease in the elderly: Response to and optimal spacing of night time dosing with levodopa. Br. J. Clin. Pharmacol. 24(5), 637-643 (1987
79. Reichmann H, Cooper J, Rolfe K, Martinez-Martin P. Sleep duration and "on" time during different periods of the day and night in patients with advanced Parkinson's disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis. 354760 (2011
80. Morita A, Okuma Y, Kamei S et al. Pramipexole reduces the prevalence of fatigue in patients with parkinson's disease. Intern. Med. 50(19), 2163-2168 (2011
81. Abe K, Takanashi M, Yanagihara T, Sakoda S. Pergolide mesilate may improve fatigue in patients with parkinson's disease. Behav. Neurol. 13(3-4), 117-121 (2001
82. Ghys L, Surmann E, Whitesides J, Boroojerdi B. Effect of rotigotine on sleep and quality of life in parkinson's disease patients: Post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin. Pharmacother 12(13), 1985-1998 (2011
83. Schestatsky P, Kumru H, Valls-Solé J et al. Neurophysiologic study of central pain in patients with parkinson disease. Neurology 69(23), 2162-2169 (2007
84. Ha AD, Jankovic J. Pain in parkinson's disease. Mov. Disord. 27(4), 485-491 (2012
85. Brefel-Courbon C, Payoux P, Thalamas C et al. Effect of levodopa on pain threshold in parkinson's disease: A clinical and positron emission tomography study. Mov. Disord. 20(12), 1557-1563 (2005
86. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C et al. Levodopa raises objective pain threshold in parkinson's disease: A RIII reflex study. J. Neurol. Neurosurg. Psychiatry 78(10), 1140-1142 (2007
87. Dellapina E, Gerdelat-Mas A, Ory-Magne F et al. Apomorphine effect on pain threshold in parkinson's disease: A clinical and positron emission tomography study. Mov. Disord. 26(1), 153-157 (2011
88. Park A, Stacy M. Dopamine-induced nonmotor symptoms of parkinson's disease. Parkinson's Dis. 485063 (2011
89. Weintraub D, Koester J, Potenza MN et al. Impulse control disorders in parkinson disease: A cross-sectional study of 3090 patients. Arch. Neurol. 67(5), 589-595 (2010
90. Hassan A, Bower JH, Kumar N et al. Dopamine agonist-triggered pathological behaviors: Surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat. Disord. 17(4), 260-264 (2011
91. Auyeung M, Tsoi TH, Tang WK et al. Impulse control disorders in Chinese Parkinson's disease patients: The effect of ergot derived dopamine agonist. Parkinsonism Relat. Disord. 17(8), 635-637 (2011
92. Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with parkinson's disease. CNS Drugs 25(3), 203-212 (2011
93. Swick TJ. Parkinson's disease and sleep/ wake disturbances. Parkinson's Dis. 205471 (2012
94. Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA. Excessive daytime sleepiness and its risk factors in incident Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 84(2), 233-234 (2013
95. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch. Neurol. 61(1), 97-102 (2004
96. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in parkinson's disease. Mov. Disord. 18(6), 659-667 (2003
97. Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: A prospective, open-label extension study. Parkinsonism Relat. Disord. 18(5), 488-493 (2012
98. Johns MW. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 14(6), 540-545 (1991